WASHINGTON, D.C. — The U.S. Senate has passed, by voice vote, the “Recalcitrant Cancer Research Act,” which would coordinate research of the forms of cancer that have the lowest survival rates.
The bipartisan cancer research measure was added an amendment to the National Defense Authorization Act of 2012, which could gain approval in the U.S. Senate as early as next week. The U.S. House passed a free-standing version of the legislation in September.
The Recalcitrant Cancer Research Act would help the National Cancer Institute’s efforts to improve prevention, diagnosis and treatment of cancers with high mortality rates. Research advancements in the fight against pancreatic, lung, liver, and ovarian cancers have lagged behind gains made in fighting all other cancers, which have improved from 50 to 67 percent in the last 40 years.
“I am very pleased that the U.S. Senate has passed this important legislation which seeks to improve prevention, diagnosis and treatment of cancers with high mortality rates,” said U.S. Rep. Leonard Lance (R-NJ-7), who co-sponsored the House version of the bill. “I applaud the efforts of U.S. Senator Sheldon Whitehouse, who shepherded the measure through the Senate, and my friend and colleague Congresswoman Anna Eshoo for joining me as strong advocates for cancer research.”
Every member of New Jersey’s House delegation signed on to the bill as a co-sponsor, except for Rep. Scott Garrett (R-NJ-5). U.S. Sen. Frank Lautenberg (D-NJ) is a co-sponsor of the stand-alone version of the bill in the Senate.
Connect with NJTODAY.NET
Join NJTODAY.NET's free Email List to receive occasional updates delivered right to your email address!